Screener
Viridian Therapeutics, Inc. VRDN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s accounts payable?
- Viridian Therapeutics, Inc. (VRDN) reported accounts payable of $8.65M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s accounts payable changed year-over-year?
- Viridian Therapeutics, Inc.'s accounts payable increased by 1.6% year-over-year, from $8.52M to $8.65M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s accounts payable has grown at a 66.9% compound annual growth rate (CAGR), from $670K to $8.68M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Viridian Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude